Pre‐Treatment Serum Albumin Concentration Predicts Clinical Benefit of Long‐Term Albumin in Patients With Cirrhosis and Ascites
United European Gastroenterology Journal · 2026-07 · 14 (6)
DOI: 10.1002/ueg2.70258 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift United European Gastroenterology Journal, online erschienen am 11.07.2026. Verfasst von Enrico Pompili und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Ascites, Liver Cirrhosis, Serum Albumin. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agenzia Italiana del Farmaco, Ministero della Salute.
Abstract (Originalsprache)
Background and Aims The benefit of long‐term albumin (LTA) in improving survival and reducing complications in patients with cirrhosis and ascites is not consistently observed across studies, possibly reflecting differences in patient populations and treatment regimens. This study aimed to determine whether baseline serum albumin (SA) levels can predict which patients are most likely to benefit from LTA therapy.
Methods
A post hoc analysis of the ANSWER trial was performed in 431 patients randomized to receive standard medical treatment (SMT) alone or SMT plus human albumin (SMT + HA). The interaction between baseline SA and LTA was investigated using competing‐risk survival analysis. The primary endpoint was 18‐month survival. Secondary endpoints included the incidence of cirrhosis‐related complications and hospitalizations.
Results
A significant treatment‐by‐albumin non‐linear interaction was found ( p = 0.010), indicating heterogeneity of treatment effect across baseline SA levels with the upper bound of the region of statistically demonstrable benefit occurring at approximately 3.2 g/dL (sHR 0.53, 95% CI 0.28–0.99). In patients with SA ≤ 3.2 g/dL, 18‐month survival was significantly higher in the SMT + HA group compared with SMT alone (HR 0.47, 95% CI 0.29–0.77; p = 0.0021). No significant survival difference could be demonstrated in patients with SA > 3.2 g/dL (HR 1.04, 95% CI 0.41–2.63; p = 0.93). Regardless of baseline SA levels, LTA was associated with improved ascites control and reduced rates of complications and hospitalizations.
Conclusions
LTA provides survival and morbidity benefits in patients with mild‐to‐moderate hypoalbuminemia, whereas in patients with normal SA levels, its benefit appears mainly limited to morbidity reduction. Baseline SA may therefore help in prioritizing LTA therapy when resources are constrained.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Surgical Sciences, Alma Mater Studiorum University of Bologna, Bologna, Italy.
- Unit of Semeiotics, Liver and Alcohol-related Diseases, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
- Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy.
- Unit of Internal Medicine and Hepatology, Department of Medicine-DIMED, University and Hospital of Padova, Padova, Italy.
- Division of Gastroenterology and Hepatology, Città Della Salute e Della Scienza Hospital, University of Turin, Turin, Italy.
- Department of Clinical and Experimental Medicine, University of Catania, Catania, Italy.
ORCID-Profile: Enrico Pompili, Giacomo Zaccherini, Stefano Fagiuoli, Fabio Marra, Giulia Iannone, Oliviero Riggio, Maurizio Baldassarre, Paolo Caraceni
Förderung
- Agenzia Italiana del Farmaco, Ministero della Salute
Zitieren
APA
Pompili, E., Zaccherini, G., Nardelli, S., Piano, S., Alessandria, C., Neri, S., Foschi, F. G., Levantesi, F., Airoldi, A., Simone, L., Svegliati-Baroni, G., Fagiuoli, S., Marra, F., Cozzolongo, R., Iannone, G., Biselli, M., Riggio, O., Angeli, P., Bernardi, M., …, & ANSWER Study Investigators (2026). Pre‐Treatment Serum Albumin Concentration Predicts Clinical Benefit of Long‐Term Albumin in Patients With Cirrhosis and Ascites. United European Gastroenterology Journal, 14(6). https://doi.org/10.1002/ueg2.70258
Vancouver
Pompili E, Zaccherini G, Nardelli S, Piano S, Alessandria C, Neri S, et al. Pre‐Treatment Serum Albumin Concentration Predicts Clinical Benefit of Long‐Term Albumin in Patients With Cirrhosis and Ascites. United European Gastroenterology Journal. 2026;14(6). doi:10.1002/ueg2.70258
BibTeX
@article{Pompili2026,
author = {Pompili, Enrico and Zaccherini, Giacomo and Nardelli, Silvia and Piano, Salvatore and Alessandria, Carlo and Neri, Sergio and Foschi, Francesco Giuseppe and Levantesi, Fabio and Airoldi, Aldo and Simone, Loredana and Svegliati-Baroni, Gianluca and Fagiuoli, Stefano and Marra, Fabio and Cozzolongo, Raffaele and Iannone, Giulia and Biselli, Maurizio and Riggio, Oliviero and Angeli, Paolo and Bernardi, Mauro and Baldassarre, Maurizio and Caraceni, Paolo and ANSWER Study Investigators, ANSWER Study Investigators},
title = {Pre‐Treatment Serum Albumin Concentration Predicts Clinical Benefit of Long‐Term Albumin in Patients With Cirrhosis and Ascites},
journal = {United European Gastroenterology Journal},
year = {2026},
volume = {14},
number = {6},
doi = {10.1002/ueg2.70258}
}
EUVIMED